An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Public ClinicalTrials.gov record NCT01592370. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
Study identification
- NCT ID
- NCT01592370
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 320 participants
Conditions and interventions
Interventions
- Nivolumab Biological
- Ipilimumab Biological
- Lirilumab Biological
- Daratumumab Biological
- Pomalidomide Drug
- Dexamethasone Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2012
- Primary completion
- Sep 24, 2020
- Completion
- Jul 8, 2024
- Last update posted
- Oct 21, 2025
2012 – 2024
United States locations
- U.S. sites
- 32
- U.S. states
- 18
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0035 | Clovis | California | 93611 | — |
| Division Of Hematology & Oncology Ctr. For Health Sciences | Los Angeles | California | 90095 | — |
| Local Institution - 0012 | Los Angeles | California | 90095 | — |
| Local Institution - 0017 | Aurora | Colorado | 80045 | — |
| Local Institution - 013 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0023 | Orlando | Florida | 32804 | — |
| Local Institution - 0037 | Skokie | Illinois | 60077 | — |
| Local Institution - 0019 | Indianapolis | Indiana | 46202 | — |
| Local Institution - 0018 | Westwood | Kansas | 66205 | — |
| Local Institution - 0003 | Baltimore | Maryland | 21231 | — |
| The Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21231 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Local Institution - 0009 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0015 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0011 | Ann Arbor | Michigan | 48109 | — |
| University Of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 0002 | Rochester | Minnesota | 55905 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Local Institution - 0033 | Omaha | Nebraska | 68130 | — |
| John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0014 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0001 | New York | New York | 10065 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Local Institution - 0028 | Columbus | Ohio | 43210 | — |
| Local Institution - 0006 | Portland | Oregon | 97239 | — |
| OHSU Center for Hematologic Malignancies | Portland | Oregon | 97239 | — |
| Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 0007 | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Local Institution - 0004 | Philadelphia | Pennsylvania | 19111 | — |
| Huntsman Cancer Institute At The Univ. Of Utah | Salt Lake City | Utah | 84112 | — |
| Local Institution - 0005 | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
Recently updated Multiple Myeloma trials
Other public records listing Multiple Myeloma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07783607: MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Not yet recruiting
- NCT07776964: Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) Not yet recruiting
- NCT07285239: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Recruiting
- NCT05976555: Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma Recruiting
- NCT07637578: A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma Recruiting
- NCT07589634: A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01592370, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 21, 2025 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01592370 live on ClinicalTrials.gov.